Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 1Biliary Tract Neoplasms 1

Interventions

Gemcitabine 11Cisplatin 8pembrolizumab 2Oxaliplatin 2Nivolumab 2Docetaxel 2Capecitabine 2trametinib 1titanium silicide 1telotristat ethyl 1sovateltide 1niraparib 1milademetan 1folfirinox 1dostarlimab 1devimistat 1cytokine inducible SH2-containing protein 1brigimadlin 1bintrafusp alfa protein, human 1becatecarin 1adagrasib 1Sorafenib 1S 1 (combination) 1Pancreaticojejunostomy 1NUC-1031 1Leucovorin 1Hydroxychloroquine 1Fluorouracil 1Cetuximab 1Catheter Ablation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Biliary Tract Neoplasms × sovateltide × Clear all
NCT01773785 2021-10-13

Phase II Study of SPI-1620 in Combination With Docetaxel as a Second-Line to Treat Biliary Cancer

Spectrum Pharmaceuticals, Inc

Phase 2 Terminated
30 enrolled
Gastrointestinal

Biliary Tract Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡